| Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. | |
| | |
MedLine Citation:
|
PMID: 21473971 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. METHODS: The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. RESULTS: There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. CONCLUSIONS: Polypills have the potential to lower CVD incidence substantially among US adults. |
| | |
Authors:
|
Paul Muntner; Devin Mann; Rachel P Wildman; Daichi Shimbo; Valentin Fuster; Mark Woodward |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American heart journal Volume: 161 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-08 Completed Date: 2011-06-14 Revised Date: 2012-04-04 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 719-25 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2011 Mosby, Inc. All rights reserved. |
Affiliation:
|
Department of Epidemiology and Medicine, University of Alabama at Birmingham, 35294, USA. pmuntner@uab.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases
/
drug therapy*,
epidemiology*,
prevention & control Drug Combinations* Female Humans Incidence Male Middle Aged Questionnaires Risk Factors |
| Grant Support | |
ID/Acronym/Agency:
|
R21 HL089625-01A1/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male phy...
Next Document: Performance-based functional assessment of patients undergoing transcatheter aortic valve implantati...